spacer
home > ebr > summer 2003 > losing our minds - what the future holds for the treatment of neurodegenerative disorders
PUBLICATIONS
European Biopharmaceutical Review

Losing Our Minds - What the Future Holds for the Treatment of Neurodegenerative Disorders

The words Alzheimer's or Parkinson's can strike terror in anyone's mind, particularly those of us aged over 50. With the average age of the western world's population rising, a disturbing flipside is that an increasing number of those that enter their 60s and beyond are falling victim to neurodegenerative conditions such as Alzheimer's, Parkinson's and stroke. Billions of dollars have been spent on developing novel effective treatments for these conditions with little success. More importantly, treatments that could actually modify the progress of these diseases rather than merely alleviate some of their symptoms, are urgently required. Demand for new and more effective drugs will therefore continue to intensify. Fortunately, there are now signs of light at the end of the tunnel and the near future could see significant progress in the battle to win back our minds.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Itzchak Angel, Vice President Research and Development at D-Pharm Ltd

Dr Angel joined D-Pharm Ltd, a biopharmaceutical company developing lipid-based drugs for the treatment of central nervous system disorders, cancer and autoimmune diseases, as Vice President of Research & Development in 1998.

He obtained his PhD from the University of Hamburg (1982) and did postdoctoral work at the NIH in the US. Formerly, he was Head of the Pharmacology Department at Synthelabo (France). Dr Angel has over 15 years' experience with preclinical and clinical development programmes in a wide range of therapeutic fields.

spacer
Dr Itzchak Angel
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

White Papers
 
Industry Events

BioPharm America™ 2019—12th Annual International Partnering Conference

11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. Life science executives from around the world gather to identify, meet and to enter into strategic relationships facilitated by partneringONE®, the world’s leading web-based partnering system. BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates from over 500 companies who participated in 2,300+ scheduled one-to-one meetings. BioPharm America is now part of Biotech Week Boston, and together they draw a total of over 4,500 life science leaders, scientists and innovators.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement